Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 333 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06044337Enrolling by invitationPhase 3
Long-term safety study of litifilimab for skin lupus
This study is a long-term follow-up for people who already completed a 52-week study of the study drug litifilimab for active skin lupus. It will check the safety of continued treatment and see if it keeps helping symptoms.
Birmingham, AlabamaAges 18 years+ - NCT05714930Recruiting
Treating lupus symptoms to a clear goal
This study looks at a “treat-to-target” approach for people with systemic lupus erythematosus (SLE) to help control symptoms to a specific goal. It may help guide medication changes when lupus is not fully calm yet.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT00512694Recruiting
Duke lupus registry for people with lupus
This trial is a registry that follows people with lupus to help Duke researchers learn about the disease and care. You may be able to join if you’re seen by a Duke rheumatologist and can come to follow-up visits.
Durham, North CarolinaAges 18 years+ - NCT03673748RecruitingPhase 2
Mesenchymal stem cell treatment for lupus kidney inflammation
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
Valladolid, ValladolidAges 18 years+ - NCT03543839RecruitingPhase 4
Belimumab for early lupus activity in the first two years
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Manhasset, New YorkAges 18 years+ - NCT07262983RecruitingPhase 1
Baricitinib for Job syndrome with lupus or eczema
This study tests if baricitinib, a pill that changes how your immune system works, is safe and tolerable for people with Job syndrome who also have lupus-like disease or severe eczema. It might offer a new treatment option for these skin and immune problems.
Bethesda, MarylandAges 12–120 - NCT05207358RecruitingPhase 4
Lower steroid use in active lupus kidney inflammation
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
BucharestAges 18–80 - NCT05443516Recruiting
Blood and urine markers in active lupus kidney disease
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
BrusselsAges 18–70 - NCT06166199Recruiting
High-intensity interval training for lupus patients
This study tests whether high-intensity interval training (short bursts of intense exercise) can help people with systemic lupus erythematosus (SLE, an autoimmune disease). It aims to see if this type of exercise is safe and improves symptoms.
Stockholm, HuddingeAges 18 years+ - NCT06058078RecruitingPhase 2
Cell therapy for active lupus nephritis
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
Nanjing, JiangsuAges 18–65 - NCT06277427Recruiting
CAR-T cell therapy for refractory vasculitis and lupus nephritis
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Wuhan, HubeiAges 18–70 - NCT06406205RecruitingPhase 3
Study of QLG1074 for active lupus nephritis
This trial tests a new medicine called QLG1074 added to standard treatments for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the combination helps control the disease better.
Bengbu, AnhuiAges 18–75 - NCT06497387RecruitingEarly Phase 1
PRG-1801 for stubborn lupus kidney and IgG4 disease
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Wuhan, HubeiAges 18 years+ - NCT06497361RecruitingEarly Phase 1
PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Wuhan, HubeiAges 18 years+ - NCT05394922Recruiting
Study of sugar patterns in lupus anti-DNA antibodies
This study looks at the “sugar coating” on anti-DNA antibodies in people with lupus. The goal is to better understand these antibody patterns, which may help improve how lupus is studied or treated in the future.
MontpellierAges 18–80 - NCT07751848RecruitingPhase 3
Study of anifrolumab for Chinese patients with active lupus
This trial tests anifrolumab, an investigational drug that may help reduce lupus activity in people with moderate-to-severe disease. If you have active lupus despite current treatments, this study might offer a new option.
BeijingAges 18–70 - NCT06593041Recruiting
Platelets in lupus and other autoimmune diseases
This study looks at how platelets (small blood cells that help with clotting) might play a role in autoimmune diseases like lupus. By understanding this, researchers hope to find new ways to treat these conditions.
Strasbourg, FranceAges 18–70 - NCT06631404Recruiting
Ultrasound test for lupus kidney activity
This trial uses an ultrasound to measure kidney blood flow in people with lupus kidney disease. The goal is to see if this simple test can tell how active the disease is, which might help doctors adjust treatment without needing frequent biopsies.
SohagAges 18–50 - NCT07700940RecruitingPhase 4
Empagliflozin for kidney function in lupus nephritis
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Banī SuwayfAges 18–65 - NCT07691970RecruitingPhase 3
Continued treatment study for people who benefited from anifrolumab
This study lets people who finished a previous anifrolumab (Saphnelo) trial and saw benefits continue getting the treatment. It aims to see how well the drug works over a longer time.
Phoenix, ArizonaAges 5–80 - NCT07694336RecruitingPhase 2
Quinacrine for skin lupus
This study tests if quinacrine, an oral drug, improves skin rashes caused by lupus. You may be eligible if you have a type of skin lupus called SCLE or DLE that hasn't improved with standard treatments like steroids or hydroxychloroquine.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT07666711Recruiting
Kidney biomarker study for lupus patients
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
Oslo, OsloAges 18 years+ - NCT06682507Recruiting
Lupus nephritis long-term study
This study follows patients with lupus nephritis (kidney inflammation caused by lupus) over time to learn more about the disease and improve care. You may join if you have had a kidney biopsy confirming lupus nephritis at this hospital.
Guangzhou, GuangdongAges 14 years+
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 333 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.